Diagnosis of antifungal drug resistance mechanisms in fungal pathogens: Transcriptional gene regulation

Current Fungal Infection Reports

Volumn 5, Issue 3, 2011, Pages 157-167

  Sanglard, Dominique ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Antifungal drug resistance; Aspergillus; Candida; Diagnosis; Multidrug transporters; Mutations

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; ECHINOCANDIN; FLUCONAZOLE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; DERMATOMYCOSIS; DRUG INDICATION; FUNGAL GENE; FUNGAL GENETICS; FUNGUS; GENE CONTROL; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; MYCOSIS; NONHUMAN; SYSTEMIC MYCOSIS; TRANSCRIPTION REGULATION;

EID: 80755153698     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-011-0055-9     Document Type: Article

References (111)

1. Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008;14 Suppl 4:5-24. (Pubitemid 351593913)
2. Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009;52:197-205.
3. Thompson G, Cadena J, Patterson T. Overview of antifungal agents. Clin Chest Med. 2009;30:203-15.
4. Akins RA. An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol. 2005;43:285-318. (Pubitemid 41030457)
5. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002;2:73-85. (Pubitemid 36114141)
6. Sanglard D. Resistance of human fungal pathogens to antifungal drugs. Curr Opin Microbiol. 2002;5:379-85.
7. Skaggs B, Alexander J, Pierson C, et al. Cloning and characterization of the Saccharomyces cerevisiae C-22 sterol desaturase gene, encoding a second cytochrome P-450 involved in ergosterol biosynthesis. Gene. 1996;169:105-9. (Pubitemid 26076619)
8. Sheehan D, Hitchcock C, Sibley C. Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999;12:40-79. (Pubitemid 29055953)
9. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007;10:121-30. (Pubitemid 47031054)
10. Arikan S. Current status of antifungal susceptibility testing methods. Med Mycol. 2007;45:569-87. (Pubitemid 350176707)
11. Pfaller MA, Andes D, Diekema DJ, et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat. 2010;13:180-95. This remarkable study compares two different methods for antifungal susceptibility testing and attempts to unify breakpoint values obtained by these methods.
12. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev. 2007;20:391-408. (Pubitemid 47175010)
13. Cuesta I, Bielza C, Larranaga P, et al. data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2009;53:2949-54.
14. Cuesta I, Bielza C, Cuenca-Estrella M, et al. Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrob Agents Chemother. 2010;54:1541-6.
15. Rodriguez-Tudela JL, Arendrup MC, Cuenca-Estrella M, et al. EUCAST breakpoints for antifungals. Drug News Perspect. 2010;23:93.
16. Pfaller M, Diekema D, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol. 2008;46:2620-9.
17. Pfaller MA, Moet GJ, Messer SA, et al. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother. 2011;55:561-6.
18. Snelders E, van der Lee H, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:e219. This work demonstrates that azole resistance in A. fumigatus has probably spread from the use of azoles in the environment.
19. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51:1897-904. (Pubitemid 46903071)
20. Morio F, Loge C, Besse B, et al. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azolesusceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis. 2010;66:373-84.
21. Marichal P, Koymans L, Willemsens S, et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology. 1999;145(Pt 10):2701-13. (Pubitemid 29485885)
22. Kudo M, Ohi M, Aoyama Y, et al. Effects of Y132H and F145L substitutions on the activity, azole resistance and spectral properties of Candida albicans sterol 14-demethylase P450 (CYP51): a live example showing the selection of altered P450 through interaction with environmental compounds. J Biochem (Tokyo). 2005;137:625-32. (Pubitemid 40874541)
23. Kelly S, Lamb D, Loeffler J, et al. The G464S amino acid substitution in Candida albicans sterol 14alpha-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem Biophys Res Commun. 1999;262:174-9. (Pubitemid 29412643)
24. Kelly SL, Lamb DC, Kelly DE. Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol Lett. 1999;180:171-5. (Pubitemid 29507563)
25. Lamb D, Kelly D, White T, et al. The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance through reduced affinity. Antimicrob Agents Chemother. 2000;44:63-7. (Pubitemid 30010673)
26. Sanglard D, Ischer F, Koymans L, et al. Amino acid substitutions in the cytochrome P450 lanosterol 14?-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contributing to the resistance to azole antifungal agents. Antimicrob Agent Chemother. 1998;42:241-53. (Pubitemid 28114426)
27. Asai K, Tsuchimori N, Okonogi K, et al. Formation of azoleresistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob Agents Chemother. 1999;43:1163-9. (Pubitemid 29214741)
28. Favre B, Didmon M, Ryder NS. Multiple amino acid substitutions in lanosterol 14alpha-demethylase contribute to azole resistance in Candida albicans. Microbiology. 1999;145(Pt 10):2715-25. (Pubitemid 29485886)
29. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1997;41:1482-7. (Pubitemid 27289672)
30. Sanglard D, Kuchler K, Ischer F, et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother. 1995;39:2378-86.
31. Perea S, Lopez-Ribot J, Kirkpatrick W, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2001;45:2676-84. (Pubitemid 32906656)
32. Marichal P, Vanden Bossche H, Odds FC, et al. Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother. 1997;41:2229-37. (Pubitemid 27422218)
33. Vandeputte P, Larcher G, Berges T, et al. Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob Agents Chemother. 2005;49:4608-15. (Pubitemid 41552590)
34. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol. 2011;49 Suppl 1:S90-5.
35. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, et al. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2003;47:1120-4.
36. Mann PA, Parmegiani RM, Wei S-Q, et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother. 2003;47:577-81. (Pubitemid 36158085)
37. Garcia-Effron G, Dilger A, Alcazar-Fuoli L, et al. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J Clin Microbiol. 2008;46:1200-6. (Pubitemid 351563556)
38. Rodero L, Mellado E, Rodriguez A, et al. G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob Agents Chemother. 2003;47:3653-6. (Pubitemid 37345742)
39. Sionov E, Chang Y, Garraffo H, et al. Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob Agents Chemother. 2009;53:2804-15.
40. Sionov E, Lee H, Chang Y, et al. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 2010;6: e1000848. This study reports the molecular basis for azole heteroresistance.
41. Douglas C, D'Ippolito J, Shei G, et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1, 3-beta-Dglucan synthase inhibitors. Antimicrob Agents Chemother. 1997;41:2471-9. (Pubitemid 27467559)
42. Park S, Kelly R, Kahn J, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother. 2005;49:3264-73. (Pubitemid 41060570)
43. Garcia-Effron G, Kontoyiannis D, Lewis R, et al. Caspofunginresistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother. 2008;52:4181-3.
44. Cleary J, Garcia-Effron G, Chapman S, et al. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother. 2008;52:2263-5. (Pubitemid 351758575)
45. Rocha E, Garcia-Effron G, Park S, et al. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother. 2007;51:4174-6. (Pubitemid 350057823)
46. Garcia-Effron G, Katiyar SK, Park S, et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2008;52:2305-12. (Pubitemid 351915657)
47. Thompson G, Wiederhold N, Vallor A, et al. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother. 2008;52:3783-5.
48. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2006;50:2892-4. (Pubitemid 44198725)
49. Sanglard D, Ischer F, Monod M, et al. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC-transporter gene. Microbiology. 1997;143:405-16. (Pubitemid 27092176)
50. Posteraro B, Sanguinetti M, Sanglard D, et al. Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole. Mol Microbiol. 2003;47:357-71. (Pubitemid 36121027)
51. Sanglard D, Ischer F, Bille J. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob Agents Chemother. 2001;45:1174-83. (Pubitemid 32230999)
52. Sanglard D, Ischer F, Calabrese D, et al. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother. 1999;43:2753-65. (Pubitemid 29519560)
53. Torelli R, Posteraro B, Ferrari S, et al. The ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata. Mol Microbiol. 2008;68:186-201. (Pubitemid 351363785)
54. Wirsching S, Moran G, Sullivan D, et al. MDR1-mediated drug resistance in Candida dubliniensis. Antimicrob Agents Chemother. 2001;45:3416-21. (Pubitemid 33107855)
55. Schubert S, Rogers P, Morschhauser J. Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazoleresistant Candida dubliniensis strains. Antimicrob Agents Chemother. 2008;52:4274-80.
56. Sa-Correia I, dos Santos S, Teixeira M, et al. Drug: H+ antiporters in chemical stress response in yeast. Trends Microbiol. 2009;17:22-31.
57. Gaur M, Puri N, Manoharlal R, et al. MFS transportome of the human pathogenic yeast Candida albicans. BMC Genomics. 2008;9:579.
58. de Micheli M, Bille J, Schueller C, et al. A common drugresponsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance. Mol Microbiol. 2002;43:1197-214. (Pubitemid 34304537)
59. Hikkel I, Lucau-Danila A, Delaveau T, et al. A general strategy to uncover transcription factor properties identifies a new regulator of drug resistance in yeast. J Biol Chem. 2003;278:11427-32. (Pubitemid 36792701)
60. Kren A, Mamnun YM, Bauer BE, et al. War1p, a novel transcription factor controlling weak acid stress response in yeast. Mol Cell Biol. 2003;23:1775-85. (Pubitemid 36246057)
61. Mendizabal I, Rios G, Mulet J, et al. Yeast putative transcription factors involved in salt tolerance. FEBS Lett. 1998;425:323-8. (Pubitemid 28178915)
62. Schjerling P, Holmberg S. Comparative amino acid sequence analysis of the C6 zinc cluster family of transcriptional regulators. Nucleic Acids Res. 1996;24:4599-607. (Pubitemid 26413334)
63. Rustad T, Stevens D, Pfaller M, et al. Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology. 2002;148:1061-72. (Pubitemid 34436781)
64. Coste AT, Karababa M, Ischer F, et al. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell. 2004;3:1639-52. (Pubitemid 40025121)
65. Lamoureux J, Stuart D, Tsang R, et al. Structure of the sporulation-specific transcription factor Ndt80 bound to DNA. EMBO J. 2002;21:5721-32.
66. Chen C-G, Yang Y-L, Shih H-I, et al. CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1. Antimicrob Agents Chemother. 2004;48:4505-12. (Pubitemid 39577646)
67. Sellam A, Tebbji F, Nantel A. Role of Ndt80p in sterol metabolism regulation and azole resistance in Candida albicans. Eukaryot Cell. 2009;8:1174-83.
68. Vermitsky J-P, Edlind TD. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob Agents Chemother. 2004;48:3773-81. (Pubitemid 39304602)
69. Vermitsky J-P, Earhart KD, Smith WL, et al. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies.Mol Microbiol. 2006;61:704-22. (Pubitemid 44324094)
70. Tsai H, Krol A, Sarti K, et al. Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob Agents Chemother. 2006;50:1384-92.
71. Ferrari S, Ischer F, Calabrese D, et al. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog. 2009;5: e1000268.
72. Caudle KE, Barker KS, Wiederhold NP, et al. Genome-wide expression profile analysis of the Candida glabrata Pdr1 regulon. Eukaryot Cell. 2011;10:373-83.
73. Harry JB, Oliver BG, Song JL, et al. Drug-induced regulation of the MDR1 promoter in Candida albicans. Antimicrob Agents Chemother. 2005;49:2785-92. (Pubitemid 40917592)
74. Hiller D, Stahl S, Morschhauser J. Multiple cis-acting sequences mediate upregulation of the MDR1 efflux pump in a fluconazoleresistant clinical Candida albicans isolate. Antimicrob Agents Chemother. 2006;50:2300-8. (Pubitemid 43993166)
75. Riggle P, Kumamoto C. Transcriptional regulation of MDR1, encoding a drug efflux determinant, in fluconazole-resistant Candida albicans strains through an Mcm1p binding site. Eukaryot Cell. 2006;5:1957-68. (Pubitemid 44956808)
76. Rognon B, Kozovska Z, Coste AT, et al. Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance. Microbiology. 2006;152:3701-22. (Pubitemid 46040691)
77. Znaidi S, Barker K, Weber S, et al. Identification of the Candida albicans Cap1p regulon. Eukaryot Cell. 2009;8:806-20.
78. Nguyen D, Alarco A, Raymond M. Multiple Yap1p-binding sites mediate induction of the yeast major facilitator FLR1 gene in response to drugs, oxidants, and alkylating agents. J Biol Chem. 2001;276:1138-45. (Pubitemid 32096539)
79. Lavoie H, Sellam A, Askew C, et al. A toolbox for epitopetagging and genome-wide location analysis in Candida albicans. BMC Genomics. 2008;9:578.
80. Morschhauser J, Barker K, Liu T, et al. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 2007;3:e164.
81. Chen CG, Yang YL, Tseng KY, et al. Rep1p negatively regulating MDR1 efflux pump involved in drug resistance in Candida albicans. Fungal Genet Biol. 2009;46:714-20.
82. Chen K, Miyazaki T, Tsai H, et al. The bZip transcription factor Cgap1p is involved in multidrug resistance and required for activation of multidrug transporter gene CgFLR1 in Candida glabrata. Gene. 2007;386:63-72. (Pubitemid 44920447)
83. Vik A, Rine J. Upc2p and Ecm22p, dual regulators of sterol biosynthesis in Saccharomyces cerevisiae. Mol Cell Biol. 2001;21:6395-405. (Pubitemid 32927408)
84. MacPherson S, Akache B, Weber S, et al. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob Agents Chemother. 2005;49:1745-52. (Pubitemid 40631584)
85. Silver PM, Oliver BG, White TC. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot Cell. 2004;3:1391-7. (Pubitemid 40025098)
86. Carvajal E, van den Hazel HB, Cybularz-Kolaczkowska A, et al. Molecular and phenotypic characterization of yeast PDR1 mutants that show hyperactive transcription of various ABC multidrug transporter genes. Mol Gen Genet. 1997;256:406-15.
87. MacPherson S, Larochelle M, Turcotte B. A fungal family of transcriptional regulators: the zinc cluster proteins. Microbiol Mol Biol Rev. 2006;70:583-604. (Pubitemid 44484686)
88. Coste A, Turner V, Ischer F, et al. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics. 2006;172:2139-56.
89. Znaidi S, De Deken X, Weber S, et al. The zinc cluster transcription factor Tac1p regulates PDR16 expression in Candida albicans. Mol Microbiol. 2007;66:440-52. (Pubitemid 47482385)
90. Coste AT, Crittin J, Bauser C, et al. Functional analysis of cisand trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. Eukaryot Cell. 2009;8:1250-67.
91. Dunkel N, Blass J, Rogers P, et al. Mutations in the multidrug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazoleresistant Candida albicans strains. Mol Microbiol. 2008;69:827-40. (Pubitemid 352033303)
92. Tsai H, Sammons L, Zhang X, et al. Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates. Antimicrob Agents Chemother. 2010;54:3308-17.
93. Berila N, Subik J. Molecular analysis of Candida glabrata clinical isolates. Mycopathologia. 2010;170:99-105.
94. Hoot SJ, Smith AR, Brown RP, White TC. An A643V amino acid substitution in Upc2p contributes to azole resistance in wellcharacterized clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2011;55:940-2.
95. Heilmann C, Schneider S, Barker K, et al. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. Antimicrob Agents Chemother. 2010;54:353-9.
96. Dunkel N, Liu T, Barker K, et al. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot Cell. 2008;7:1180-90. (Pubitemid 351969332)
97. Crowley J, Leak F, Shianna K, et al. A mutation in a purported regulatory gene affects control of sterol uptake in Saccharomyces cerevisiae. J Bact. 1998;180:4177-83. (Pubitemid 28373523)
98. Coste A, Selmecki A, Forche A, et al. Genotypic evolution of azole resistance mechanisms in sequential candida albicans isolates. Eukaryot Cell. 2007;6:1889-904. (Pubitemid 47585577)
99. Selmecki A, Gerami-Nejad M, Paulson C, et al. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol Microbiol. 2008;68:624-41. (Pubitemid 351490182)
100. Selmecki A, Forche A, Berman J. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science. 2006;313:367-70. (Pubitemid 44480964)
101. Perlin DS. Antifungal drug resistance: do molecular methods provide a way forward? Curr Opin Infect Dis. 2009;22:568-73.
102. Park S, Perlin D. Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb Drug Resist. 2005;11:232-8. (Pubitemid 41434167)
103. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother. 2006;50:2058-63. (Pubitemid 43807526)
104. Perlin DS, Zhao Y. Molecular diagnostic platforms for detecting Aspergillus. Med Mycol. 2009;47 Suppl 1:S223-32.
105. Balashov SV, Gardiner R, Park S, et al. Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the cyp51A gene of Aspergillus fumigatus that confer resistance to itraconazole. J Clin Microbiol. 2005;43:214-22. (Pubitemid 40096303)
106. Denning DW, Park S, Lass-Flörl C, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis. 2011;52:1123-29. This study demonstrates the power of DNA-based diagnostic tools for the detection of azole resistance in A. fumigatus, which otherwise would have been missed by conventional culture-based approaches.
107. van der Linden JWM, Snelders E, Arends JP, et al. Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens. J Clin Microbiol. 2010;48:1478-80.
108. Liu TT, Znaidi S, Barker KS, et al. Genome-wide expression and location analyses of the Candida albicans Tac1p regulon. Eukaryot Cell. 2007;6:2122-38. (Pubitemid 350221281)
109. Hoot S, Brown R, Oliver B, et al. The UPC2 promoter in Candida albicans contains two cis-acting elements that bind directly to Upc2p, resulting in transcriptional autoregulation. Eukaryot Cell. 2010;9:1354-62.
110. Alarco A, Raymond M. The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans. J Bact. 1999;181:700-8. (Pubitemid 29061549)
111. Shen H, An M-M, Wang DJ, et al. Fcr1p inhibits development of fluconazole resistance in Candida albicans by abolishing CDR1 induction. Biol Pharm Bull. 2007;30:68-73. (Pubitemid 46066322)